Bone turnover markers (BTM) provide useful data to titrate the optimal dosing regimes for patients within 3–6 months as compared to 1–2 years using bone mineral density (BMD). Serum obtained under standardised conditions (fasting, early morning) should be tested using a precise automated immunoassay for a panel of bone markers that includes a resorption marker — C-terminal cross-linked telopeptide of bone collagen (CTX) — and formation markers — Procollagen Type 1 N-terminal Propeptide (P1NP) and Osteocalcin (OC).
deVilliersTJ. Bone health and osteoporosis in postmenopausal women. Best Pract Res Clin Obstet Gynecol2009; 23(1):73–85.
2.
BrownJPAlbertCNassarBAAdachiJDColeDDavisonKS. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem2009;42(10–11):929–42.
3.
BergmannPBodyJJBoonenSBoutsenYDevogelaerJPGoemaereS. Evidence-Based Guidelines for the Use of Biochemical Markers of Bone Turnover in the Selection and Monitoring of Bisphosphonate Treatment in Osteoporosis: A Consensus Document of the Belgian Bone Club. Int J Clin Pract2009;63(1):19–26.
4.
CompstonJ. Monitoring osteoporosis treatment. Best Pract Res Clin Rheum2009;23(6):781–8.
5.
DavisonKSKendlerDLAmmannPBauerDCDempsterDWDianL. Assessing fracture risk and effects of osteoporosis drugs: Bone mineral density and beyond. Am J Med2009;122(11):992–7.
6.
BaimSMillerPD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting osteonecrosis of the jaw. J Bone Miner Res2009;24(4):561–74.
7.
LashRWNicholsonJMVelezLvan HarrisonRMcCortJ. Diagnosis and management of osteoporosis. Prim Care. 2009;36(1):181–98, x.
8.
CompstonJCooperACooperCFrancisRKanisJAMarshD. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas2009;62(2):105–8.
9.
Schmidt-GaykHSpanuthEKottingJBartlRFelsenbergDPfeilschifterJ. Performance evaluation of automated assays for beta-crosslaps, N-mid-osteocalcin and intact parathyroid hormone (BIOROSE Multicenter study). Clin Chem Lab Med2004;42(1):90–95.
10.
GarneroPVergnaudPHoyleN. Evaluation of a fully automated serum assay for total N-terminal propeptide of type 1 collagen in postmenopausal osteoporosis. Clin Chem2008; 54(1):188–96.
11.
LewieckiEM. Treatment of osteoporosis with denosumab. Maturitas2010;66(2):182–6.
12.
RouxS. New treatment targets in osteoporosis. Joint Bone Spine2010;77(3):222–8.
13.
HenriksenKNeutzsky-WulffAVBonewaldLFKarsdalMA. Local communication on and within bone controls bone remodeling. Bone2009;44(6):1026–33.
14.
KubotaTMichigamiTOzonoK. Wnt signaling in bone metabolism. J Bone Miner Metab2009;27(3):265–271.
15.
EnginFLeeB. NOTCHing the bone: Insights into multi-functionality. Bone2010;46(2):274–280.
16.
O'BrienCA. Control of RANKL gene expression. Bone2010;46(4):911–919.
17.
GallagherJCSaiAJ. Molecular biology of bone remodeling: Implications for new therapeutic targets for osteoporosis. Maturitas2010;65(4):301–307.
18.
MariePJ. The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis. Bone2010;46(3):571–576.
